Business
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the
About this update from Guardant Health, Inc.
[{"type":"text","content":" PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.\n\n\nThe COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in patients with stage II colon cancer after curative-intent surgery with a planned final readout in 2026.\n\n\n“Our MRD test has great potential to help patients and their doctors stay ahead of cancer, and we remain confident about its promise to vastly improve patient care and its continued prospects for broad access and reimbursement,” said Craig Eagle, MD, Guardant Health chief medical officer.\n\n\n“We agree with the decision, based on the recent planned interim analysis, to close the COBRA study to new enrollees,” said Dr. Eagle. “The field has progressed rapidly since the study was designed over four years ago, and since the study was initiated we have made tremendous progress with multiple upgrades of our MRD test. Additionally, we have many ongoing studies that will demonstrate the effectiveness of our current MRD tests in colorectal cancer and other settings.”\n\n\nAbout Guardant Health\n\n\nGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter (X).\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests ...